This segregation occurs by an inverse mechanism, with solute-rich liquid sucked back through a solid network by solidification shrinkage.
Physical simulation experiments by Gleeble are utilized to understand the kinetics of void shrinkage in solid state bonding at high temperatures and high pressures.
It takes into account, non-catalytic gas solid reactions, the moving bed of solid particles and the shrinkage of the unreacted particle core.
Furthermore, the use of the standard Response Evaluation Criteria in Solid Tumors and tumor shrinkage as criteria for treatment response may be problematic.
A phase I study of an OX40 agonist in advanced solid tumours demonstrated tumour shrinkage of at least one metastatic lesion in 12 out of 30 subjects after one cycle of therapy (Curti et al, 2013).
When the pressure decreases, dissolved gas will release, leading to the shrinkage of the solid matrix and increment of porosity and permeability.
In addition, with the increase in cooling rate at the constant solid loading, parameters of linear shrinkage and also porosity decreased whereas strength increased significantly.
Still, the origin of the deformation remains arbitrary and the derived expressions could be used to quantify segregation due to the thermal contraction of the solid and liquid phases, the shrinkage associated with the phase transformations, and/or the mechanical deformation of the domain.
This allows avoiding shrinkage of the solid pore network at a low temperature.
Thus, it stands to reason that continued prolonged use of p28 could be a model non-toxic therapeutic option for ultimate shrinkage of advanced/recurrent solid tumours resulting in long-term progression-free survival.
Response evaluation during cancer treatment is normally based on the response evaluation criteria in solid tumours (RECIST) looking for tumour shrinkage [1].
